Worth reading
70In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
55.8
% (change in net income attributable to owners of the parent)Wording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
2022 年 5 月期 · Full yearPrevious forecast published 2021 年 7 月 14 日Net Sales49,838→54,426million
+9.2%
Operating profit542→830million
+53.0%
Ordinary income584→894million
+52.9%
Profit attributable to owners of the parent346→539million
+55.8%
Net income per share135.69→211.37yen and sen
+55.8%
The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Reason for the revision
主力商品分野の売上が期初想定以上に回復したことに加え、コロナ関連商品の医療機関の需要等も継続したため。利益面では、売上増加に伴う売上総利益の増加により、営業利益、経常利益及び親会社株主に帰属する当期純利益が期初予想を上回る見込みとなった。
Previous-period results2021年5月期：売上高70,131百万円、営業利益968百万円、経常利益1,026百万円、親会社株主に帰属する当期純利益678百万円、1株当たり当期純利益265.77円 銭
Dividend forecast revision期末配当を1株当たり41円から63円に増額。年間配当金合計も41円から63円に修正。
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | ¥49,838 million → ¥54,426 million（+9.2%） |
| Operating profit | ¥542 million → ¥830 million（+53.0%） |
| Ordinary income | ¥584 million → ¥894 million（+52.9%） |
| Profit attributable to owners of the parent | ¥346 million → ¥539 million（+55.8%） |
| Net income per share | 135.69 yen and sen → 211.37 yen and sen |
| Fiscal Period Covered | 2022 年 5 月期 |
| Period Covered | Full year |
| Publication date of previous forecast | 2021 年 7 月 14 日 |
| Previous-period results | 2021年5月期：売上高70,131百万円、営業利益968百万円、経常利益1,026百万円、親会社株主に帰属する当期純利益678百万円、1株当たり当期純利益265.77円 銭 |
| Reason for the revision | 主力商品分野の売上が期初想定以上に回復したことに加え、コロナ関連商品の医療機関の需要等も継続したため。利益面では、売上増加に伴う売上総利益の増加により、営業利益、経常利益及び親会社株主に帰属する当期純利益が期初予想を上回る見込みとなった。 |
| Dividend forecast revision | 期末配当を1株当たり41円から63円に増額。年間配当金合計も41円から63円に修正。 |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
Details and amount of extraordinary loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.医療機器備品や低侵襲治療機器など主力商品の売上が期初想定以上に回復し、感染対策機器・検査機器などコロナ関連商品の需要も継続したため。利益面では、売上増加に伴って売上総利益が増加したとしている。配当は、連結配当性向30％を基準とし、業績予想の上方修正を踏まえて増額した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.